Lucia Gabriele
Overview
Explore the profile of Lucia Gabriele including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
2721
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Offi M, Gabriele L, Romagnoli G, Lauretti L, Pallini R, DAlessandris Q
Neuro Oncol
. 2024 Jun;
26(8):1538-1539.
PMID: 38885219
No abstract available.
2.
Santagata S, Rea G, Bello A, Capiluongo A, Napolitano M, Desicato S, et al.
Br J Cancer
. 2024 May;
130(12):2016-2026.
PMID: 38704478
Background: Tregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in peripheral blood (PB)-Tregs isolated from primary RCC...
3.
Romagnoli G, DAlessandris Q, Capone I, Tavilla A, Canini I, Lapenta C, et al.
Immunology
. 2023 Oct;
171(2):198-211.
PMID: 37884280
Glioblastoma, isocitrate dehydrogenase-wildtype (GB), is the most common and aggressive primary brain malignancy with poor outcome. Immune checkpoint inhibitors (ICIs) have been tested in GB and, despite disappointing results, the...
4.
Fragale A, Stellacci E, Romagnoli G, Licursi V, Parlato S, Canini I, et al.
Int J Cancer
. 2023 Jun;
153(5):1080-1095.
PMID: 37293858
BRAF mutations are the most common oncogenic alterations in melanoma cells, supporting proliferation, invasion, metastasis and immune evasion. In patients, these aberrantly activated cellular pathways are inhibited by BRAFi whose...
5.
Lauretti L, Cenci T, Montano N, Offi M, Giordano M, Caccavella V, et al.
J Pers Med
. 2022 May;
12(5).
PMID: 35629107
The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively activated oncogenic receptor, in glioblastoma is controversial. We performed a prospective study enrolling 355 patients operated on...
6.
Frasca F, Scordio M, Santinelli L, Gabriele L, Gandini O, Criniti A, et al.
Eur J Immunol
. 2022 Apr;
52(7):1120-1128.
PMID: 35419822
A significant number of COVID-19 patients were shown to have neutralizing antibodies (NAB) against IFN; however, NAB specificity, fluctuation over time, associations with biochemical and hematological parameters, and IFN gene...
7.
Sorrentino L, Silvestri V, Oliveto G, Scordio M, Frasca F, Fracella M, et al.
Microorganisms
. 2022 Feb;
10(2).
PMID: 35208821
Type III interferons (IFN-III), also known as IFN-Lambda, have a pivotal role during SARS-CoV-2 infection. IFN-Lambda response among individuals is heterogeneous and its association with COVID-19 symptoms severity needs to...
8.
Maccari S, Buoncervello M, Ascione B, Stati T, Macchia D, Fidanza S, et al.
Br J Pharmacol
. 2021 Nov;
179(7):1371-1383.
PMID: 34766341
Background And Purpose: Recently, β-adrenoceptor blockade has emerged as a potential strategy to inhibit melanoma growth. It remains to be ascertained whether β-adrenoceptor stimulation by circulating catecholamines increases melanoma growth...
9.
Parlato S, Grisanti G, Sinibaldi G, Peruzzi G, Casciola C, Gabriele L
Lab Chip
. 2020 Dec;
21(2):234-253.
PMID: 33315027
Immunotherapy is a powerful therapeutic approach able to re-educate the immune system to fight cancer. A key player in this process is the tumor microenvironment (TME), which is a dynamic...
10.
Bracci L, Fragale A, Gabriele L, Moschella F
Front Immunol
. 2020 Nov;
11:582744.
PMID: 33193392
Immunotherapy, particularly immune checkpoint blockade and chimeric antigen receptor (CAR)-T cells, holds a great promise against cancer. These treatments have markedly improved survival in solid as well as in hematologic...